Which of the following relates directly to the management of anemia in patients undergoing dialysis?

The management of anemia in patients undergoing dialysis primarily involves the administration of erythropoiesis-stimulating agents (ESAs). These agents, such as erythropoietin, help stimulate the bone marrow to produce more red blood cells, addressing the underlying cause of anemia often seen in these patients, which is typically due to decreased production of erythropoietin as a consequence of kidney dysfunction.

While regular blood transfusions can elevate hemoglobin levels temporarily, they are not the first-line approach for chronic anemia management in dialysis patients due to risks like iron overload and immune reactions. Increased iron supplementation may be necessary, particularly when using ESAs, as they require adequate iron levels to be effective; however, iron supplementation alone does not stimulate red blood cell production. Daily blood tests may be performed to monitor hemoglobin levels and iron stores, but they do not directly manage anemia. Therefore, the administration of erythropoiesis-stimulating agents is the most direct and effective method for managing anemia in this population.